Cargando…
Pneumopathie immuno-induite : un diagnostic différentiel de la pneumopathie à SARS-CoV-2
INTRODUCTION: Immune checkpoint inhibitors have revolutionized the management of many cancers and achieved efficacy and durable response for some patients, including those with advanced cancers. However, immunotherapy is associated with side effects caused by the infiltration of immune cells into no...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SPLF. Published by Elsevier Masson SAS.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283672/ https://www.ncbi.nlm.nih.gov/pubmed/35906150 http://dx.doi.org/10.1016/j.rmr.2022.07.001 |
_version_ | 1784747376199598080 |
---|---|
author | Nigen, B. Chéné, A.-L. Liberge, R. Sagan, C. Blanc, F.-X. |
author_facet | Nigen, B. Chéné, A.-L. Liberge, R. Sagan, C. Blanc, F.-X. |
author_sort | Nigen, B. |
collection | PubMed |
description | INTRODUCTION: Immune checkpoint inhibitors have revolutionized the management of many cancers and achieved efficacy and durable response for some patients, including those with advanced cancers. However, immunotherapy is associated with side effects caused by the infiltration of immune cells into normal tissues, which can lead to disproportionate dysimmune reactions. While mostly of moderate intensity, these side effects can affect any organ, including the lung, the site of occasionally life-threatening interstitial lung disease. Their presentation can be similar to that of infectious pneumonia (COVID-19). OBSERVATIONS: We report the cases of 3 patients who presented between March and May 2020 with severe pulmonary toxicities secondary to immunotherapy, which led to with an initial hypothesis of SARS-CoV-2 pneumonia. After extensive investigations, the diagnosis of pulmonary toxicity to immunotherapy was given, and the clinical and radiological course following the initiation of corticosteroid therapy was favorable. CONCLUSION: Pulmonary toxicity secondary to immunotherapy remains a rare but potentially life-threatening side effect. The diagnostic approach requires the elimination of several differential diagnoses (infectious process, tumor progression, other etiologies of interstitial lung disease). This adverse event is reversible and evolution after initiation of corticosteroid therapy is usually favorable. |
format | Online Article Text |
id | pubmed-9283672 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SPLF. Published by Elsevier Masson SAS. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92836722022-07-15 Pneumopathie immuno-induite : un diagnostic différentiel de la pneumopathie à SARS-CoV-2 Nigen, B. Chéné, A.-L. Liberge, R. Sagan, C. Blanc, F.-X. Rev Mal Respir Cas Clinique INTRODUCTION: Immune checkpoint inhibitors have revolutionized the management of many cancers and achieved efficacy and durable response for some patients, including those with advanced cancers. However, immunotherapy is associated with side effects caused by the infiltration of immune cells into normal tissues, which can lead to disproportionate dysimmune reactions. While mostly of moderate intensity, these side effects can affect any organ, including the lung, the site of occasionally life-threatening interstitial lung disease. Their presentation can be similar to that of infectious pneumonia (COVID-19). OBSERVATIONS: We report the cases of 3 patients who presented between March and May 2020 with severe pulmonary toxicities secondary to immunotherapy, which led to with an initial hypothesis of SARS-CoV-2 pneumonia. After extensive investigations, the diagnosis of pulmonary toxicity to immunotherapy was given, and the clinical and radiological course following the initiation of corticosteroid therapy was favorable. CONCLUSION: Pulmonary toxicity secondary to immunotherapy remains a rare but potentially life-threatening side effect. The diagnostic approach requires the elimination of several differential diagnoses (infectious process, tumor progression, other etiologies of interstitial lung disease). This adverse event is reversible and evolution after initiation of corticosteroid therapy is usually favorable. SPLF. Published by Elsevier Masson SAS. 2022-09 2022-07-15 /pmc/articles/PMC9283672/ /pubmed/35906150 http://dx.doi.org/10.1016/j.rmr.2022.07.001 Text en © 2022 SPLF. Published by Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Cas Clinique Nigen, B. Chéné, A.-L. Liberge, R. Sagan, C. Blanc, F.-X. Pneumopathie immuno-induite : un diagnostic différentiel de la pneumopathie à SARS-CoV-2 |
title | Pneumopathie immuno-induite : un diagnostic différentiel de la pneumopathie à SARS-CoV-2 |
title_full | Pneumopathie immuno-induite : un diagnostic différentiel de la pneumopathie à SARS-CoV-2 |
title_fullStr | Pneumopathie immuno-induite : un diagnostic différentiel de la pneumopathie à SARS-CoV-2 |
title_full_unstemmed | Pneumopathie immuno-induite : un diagnostic différentiel de la pneumopathie à SARS-CoV-2 |
title_short | Pneumopathie immuno-induite : un diagnostic différentiel de la pneumopathie à SARS-CoV-2 |
title_sort | pneumopathie immuno-induite : un diagnostic différentiel de la pneumopathie à sars-cov-2 |
topic | Cas Clinique |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283672/ https://www.ncbi.nlm.nih.gov/pubmed/35906150 http://dx.doi.org/10.1016/j.rmr.2022.07.001 |
work_keys_str_mv | AT nigenb pneumopathieimmunoinduiteundiagnosticdifferentieldelapneumopathieasarscov2 AT cheneal pneumopathieimmunoinduiteundiagnosticdifferentieldelapneumopathieasarscov2 AT liberger pneumopathieimmunoinduiteundiagnosticdifferentieldelapneumopathieasarscov2 AT saganc pneumopathieimmunoinduiteundiagnosticdifferentieldelapneumopathieasarscov2 AT blancfx pneumopathieimmunoinduiteundiagnosticdifferentieldelapneumopathieasarscov2 |